S&CO Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 41,387 shares of the medical research company’s stock, valued at approximately $20,749,000. Thermo Fisher Scientific makes up 1.2% of S&CO Inc.’s holdings, making the stock its 22nd biggest holding.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. J. Stern & Co. LLP increased its holdings in Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares in the last quarter. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $3,072,744,000. Auto Owners Insurance Co increased its stake in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock worth $1,406,844,000 after purchasing an additional 2,423,706 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 2,183.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock worth $770,000,000 after purchasing an additional 1,270,643 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Thermo Fisher Scientific by 19.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock valued at $4,462,550,000 after buying an additional 1,230,872 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have commented on TMO shares. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $619.41.
Insider Transactions at Thermo Fisher Scientific
In related news, CEO Marc N. Casper sold 4,608 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $586.12, for a total transaction of $2,700,840.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 in the last three months. 0.33% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Trading Down 0.3%
Shares of Thermo Fisher Scientific stock opened at $586.62 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock’s 50 day simple moving average is $531.72 and its 200-day simple moving average is $508.48. The stock has a market cap of $216.90 billion, a P/E ratio of 31.56, a P/E/G ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
